Publications 2014


Bartolomeo P, Bachoud-Lévi AC, Thiebaut de Schotten M. The anatomy of cerebral achromatopsia: a reappraisal and comparison of two case reports. Cortex. 2014 Jul;56:138-44.
 
Ayache SS, Gracies JM, Ahdab R, Farhat WH, Fénelon G, Lefaucheur JP. Action-induced clonus: Underlying mechanisms revisited. Clin Neurophysiol. 2014;125:1496-9.

Désaméricq G, Dolbeau G, Verny C, Charles P, Durr A, Youssov K, Simonin C, Azulay JP, Tranchant C, Goizet C, Damier P, Broussolle E, Demonet JF, Morgado G, Cleret de Langavant L, Macquin-Mavier I, Bachoud-Lévi AC, Maison P. Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. PLoS One. 2014 Jan 15;9(1):e85430.

Désaméricq G, Schurhoff F, Meary A, Szöke A, Macquin-Mavier I, Bachoud-Lévi AC, Maison P. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014 Feb;70(2):127-34.

Desamericq G, Tissot CM, Akakpo S, Tropeano AI, Millasseau S, Macquin-Mavier I. Carotid-Femoral Pulse Wave Velocity Is Not Increased in Obesity. Am J Hypertens. 2014 Oct 9. 
Fénelon G. les hallucinations du neurologue. Pratique Neurologique – FMC  2014;5:277-286.

Salem L, Saleh N, Youssov K, Olivier A, Charles P, Scherer C, Verny C, Bachoud-Lévi AC, Maison P. The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials. Fundam Clin Pharmacol 2014; 28(6):700-10. 

Thiriez C, Gurruchaga J-M, Goujon C, Fénelon G, Palfi S. Spinal stimulation for movement disorders. Neurotherapeutics 2014;11:543-52.
 
Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014 Mar 29;383(9923):1138-46.

 


Fénelon G. les hallucinations du neurologue. Pratique Neurologique – FMC  2014;5:277-286.